ArticleMolecular and clinical oncology2014
High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor.
Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- PRDX4 expression potentially links redox adaptation to oncogenic signaling and tumor progression in pancreatic ductal adenocarcinoma.Translational oncology · 2026Article
- Low expression of SOD and PRX4 as indicators of poor prognosis and systemic inflammation in colorectal cancer.Frontiers in oncology · 2025Article
- Lymph Node Metastasis in Gastrointestinal Carcinomas: A View from a Proteomics Perspective.Current oncology (Toronto, Ont.) · 2024Review
- The combination of the low immunohistochemical expression of peroxiredoxin 4 and perilipin 2 predicts longer survival in pancreatic ductal adenocarcinoma with peroxiredoxin 4 possibly playing a main role.Histology and histopathology · 2023Article
- Article
- The Role of Peroxiredoxins in Cancer Development.Biology · 2023Review
- Expression and prognostic value of PRDX family in colon adenocarcinoma by integrating comprehensive analysis andFrontiers in oncology · 2023Article
- Essential Roles of Peroxiredoxin IV in Inflammation and Cancer.Molecules (Basel, Switzerland) · 2022Review
- Article
- Peroxiredoxin 4, a new oxidative stress marker in follicular fluid, may predictAnnals of translational medicine · 2020Article
- Review
- PRDX4 and Its Roles in Various Cancers.Technology in cancer research & treatment · 2019Review
- The prognostic values of the peroxiredoxins family in ovarian cancer.Bioscience reports · 2018Article
- Peroxiredoxins in Colorectal Cancer: Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation Sensitivity?Antioxidants (Basel, Switzerland) · 2018Review
- Effect of Derris scandens extract on a human hepatocellular carcinoma cell line.Oncology letters · 2018Article
- Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer.Antioxidants & redox signaling · 2018Review
- Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy.Oncotarget · 2017Article
- The role of peroxiredoxins in cancer.Molecular and clinical oncology · 2017Article
- Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases.Pharmacology & therapeutics · 2016Review
- The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.Cancer letters · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxiredoxin 4 (Prx4) has a number of important biological functions, such as efficient antioxidant capacity and promotion of cell proliferation and differentiation. The purpose of this study was to investigate the expression and significance of Prx4 in human colorectal cancer (CRC). Quantitative polymerase chain reaction (qPCR) was performed to detect Prx4 in 8 freshly frozen specimens of CRC and their adjacent normal tissues. In addition, immunohistochemical analysis was performed to detect Prx4 in 59 specimens of CRC and 26 of adjacent normal tissues. The immunohistochemical and qPCR results demonstrated that the expressions of the Prx4 gene and protein were higher in CRC compared to those in the adjacent normal tissues. The expression intensity of the Prx4 protein was correlated with depth of invasion (P=0.001), lymph node metastasis (P=0.006) and Dukes' classification (P=0.004) in CRC. The Kaplan-Meier survival curves revealed that high Prx4 expression was correlated with short survival time. However, the Cox proportional hazards regression analysis did not identify Prx4 as an independent prognostic marker for CRC (P>0.05). These results suggested that Prx4 may be associated with carcinogenesis and the development of CRC and it may be a prognostic marker for postoperative CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.